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Background: Epidermal growth factor receptor (EGFR) is amplified in 40% of human glioblastomas. However, most
glioblastoma patients respond poorly to anti-EGFR therapy. MicroRNAs can function as either oncogenes or tumor
suppressor genes, and have been shown to play an important role in cancer cell proliferation, invasion and apoptosis.
Whether microRNAs can impact the therapeutic effects of EGFR inhibitors in glioblastoma is unknown.
Methods: miR-566 expression levels were detected in glioma cell lines, using real-time quantitative RT-PCR (qRT-PCR).
Luciferase reporter assays and Western blots were used to validate VHL as a direct target gene of miR-566. Cell
proliferation, invasion, cell cycle distribution and apoptosis were also examined to confirm whether miR-566
inhibition could sensitize anti-EGFR therapy.
Results: In this study, we demonstrated that miR-566 is up-regulated in human glioma cell lines and inhibition of
miR-566 decreased the activity of the EGFR pathway. Lentiviral mediated inhibition of miR-566 in glioblastoma cell lines
significantly inhibited cell proliferation and invasion and led to cell cycle arrest in the G0/G1 phase. In addition, we
identified von Hippel-Lindau (VHL) as a novel functional target of miR-566. VHL regulates the formation of the β-catenin/
hypoxia-inducible factors-1α complex under miR-566 regulation.
Conclusions: miR-566 activated EGFR signaling and its inhibition sensitized glioblastoma cells to anti-EGFR therapy.
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Glioblastoma is the most common and fatal primary brain
tumor in adults [1]. The survival time varies depending on
the patient’s genetic background [2,3]. PTEN mutation and
EGFR amplification are key prognostic factors in patients
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unless otherwise stated.glioblastoma multiforme [4]. Molecular therapies targeting
EGFR have been developed in recent years, such as ge-
fitinib, but many patients do not respond well to EGFR
inhibitors, including those with non-small-cell lung
cancer or glioblastoma [5]. This is exemplified by the
EGFR pathway’s contribution to radiation or chemo re-
sistance in glioma [6].
MicroRNAs target the 3’ UTRs of oncogenes and tumor
suppressor genes therefore contributing to the tumorigen-
esis of various human cancers [7]. We previously identi-
fied a group of microRNAs (miR-21, miR-23b, miR-27b
and miR-524-5p) that regulate proliferation, invasion and
apoptosis in glioma [8-11]. Additionally, we demonstrated
that the expression profile of miR-566 as well as that of
four other miRNAs (miR-181d, miR-518b, miR-524-5p
and miR-1227) correlated with the prognosis ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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miR-518, and miR-1227 have been reported in glioma or
in other cancer types [13-15], however, there are no re-
ports about miR-566 function till now.
Numerous studies have demonstrated that miRNAs
contribute to chemotherapy resistance [16-18], most likely
by regulating pro-survival pathways involved in drug re-
sistance. Accumulating evidence suggests that microRNAs
can regulate EGFR signaling, correlate with EGFR expres-
sion and influence gefitinib’s efficacy. For example, a study
of lung cancer suggested that miRNA-128b directly regu-
lated EGFR and loss of heterozygosity (LOH) was frequent
in tumor samples, correlating significantly with the
clinical response and survival following gefitinib
treatment [19]. Furthermore, miR-21 repressed p53-
mediated apoptosis in response to chemotherapeutic
agents, such as doxorubicin and other DNA damage-
inducing agents, thereby contributing to drug resistance
in glioblastoma cells [20]. In this study, we focused on
the function of miR-566 in EGFR signaling. We hypoth-
esized that miR-566 could regulate the EGFR pathway
and influence the sensitivity of glioma cells to anti-
EGFR therapy.Figure 1 miR-566 inhibitor blocked EGFR/Akt signaling. (A) qRT-PCR a
normal astrocytes. The data shown are average fold changes (the mean ± s
each cell line relative to astrocytes. (B) Western blot (top) and real-time RT-
of glioma cell lines and astrocytes. GAPDH was used to normalize the initia
were based on the amount of target message relative to GAPDH. Bar grap
astrocytes. (C) qPCR was used to measure the expression of miR-566 in glio
are shown as the mean ± SD. **, P < 0.01. (D, E) U87 and LN229 glioma cel
real-time RT-PCR (D) and Western blot (E) were used to detect the expressResults
miR-566 is over-expressed in glioma cell lines and
activates EGFR/Akt signaling
We previously demonstrated that the expression of five
microRNAs (miR-181d, miR-518b, miR-524-5p, miR-
566 and miR-1227) were correlated with the survival of
glioblastoma patients [12]. Previous studies have clari-
fied the functions of the miR-181 family, miR-518b,
miR-524-5p and miR-1227. However, the function of
miR-566 has not been reported. To address the func-
tion of miR-566, we first examined the expression of
miR-566 in a panel of five glioma cell lines and normal
astrocytes by qPCR. The results showed that miR-566
was overexpressed in all the glioma cell lines, especially
in U87 and LN229 cells. The expression level of miR-566
was 5.1 fold in U87 and 4.7 fold in LN229 cells than miR-
566 in control astrocytes (Figure 1A). We selected these
two cell lines for further functional analysis and examined
the expression of EGFR at both the mRNA and protein
levels. Interestingly, the same expression profile was de-
tected in five glioma cell lines, including normal astrocytes
(Figure 1B). Therefore, we hypothesized that the EGFR
pathway maybe regulated by miR-566. To confirm this, analysis of miR-566 in total RNA from indicated glioma cell lines and
.e. of 3 individual experiments) of individual miR-566 expression in
PCR (bottom) were used to detect the expression of EGFR in a panel
l input of total RNA. The expression levels of the transcripts of EGFR
hs show the ratio of the expression level in each cell line to that in
ma cells that were infected with or without lenti-AS-566. The data
ls were either infected with lenti-NC or lenti-AS-566, and 48 h later,
ion of EGFR and Akt.
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constructed to down-regulate the expression of miR-566.
qPCR analysis indicated that the lentivirus could success-
fully reduce miR-566 expression by 79% and 75% in U87
and LN229 cells, respectively (Figure 1C). Finally, EGFR
and Akt expression were detected both at the mRNA and
protein levels, which revealed that the miR-566 inhibitor
deactivated EGFR/Akt signaling (Figure 1D and E).
Inhibition of miR-566 inhibits proliferation and
invasiveness of glioma cells
After demonstrating that miR-566 deactivates the EGFR/
Akt pathway, we examined miR-566’s function in glioma
cell proliferation, invasion, apoptosis and cell cycle distri-
bution. We investigated the effects of miR-566 inhibition
on the growth and viability of U87 and LN229 gliomaFigure 2 miR-566 inhibitor suppressed the proliferation and invasive
treated with lenti-NC or lenti-AS-566. After 24 h, viable cells were harvested
suspension. Cells were allowed to grow for 14 days before fixing with methan
individual experiments. (B) Mice were implanted with U87 cells pretreated wi
Tumor mass was determined by bioluminescence at day 3, 7, 11, 16 and 21. T
glioma cells were infected with lenti-NC or lenti-AS-566. After 48 h, the cell cy
analyzed 24 h after seeding in transwells (D).cells. Lenti-AS-566 significantly suppressed the colony
forming abilities of these cells (to 47% and 39%, respect-
ively; Figure 2A) compared to lenti-NC treated cells. To
examine the potential role of miR-566 in tumorigenesis,
we infected U87 cells with lenti-AS-566 or lenti-NC and
used these cells in an intracranial model, and tumor size
was assessed weekly by a luciferase bioluminescence im-
aging system. Notably, the inhibition of miR-566 expres-
sion in U87 cells resulted in delayed tumor formation and
a dramatic reduction in tumor size compared to the lenti-
NC group (Figure 2B). This result demonstrated that miR-
566 inhibits the tumorigenicity of glioma cells both
in vitro and in vivo. We then investigated how miR-566 af-
fects the invasive and apoptotic behaviors of glioma cells.
U87 and LN229 cells were infected with lenti-AS-566, and
48 h after infection, a cell invasion assay was performed.potential of glioma cells. (A) U87 and LN229 glioma cells were
and reseeded at 2000 cells/well onto 6-well plates as a single-cell
ol and staining with crystal violet. The data shown are representative of 3
th a luciferase reporter containing lenti-virus and lenti-NC or lenti-AS-566.
he data are shown as the mean ± SD. **, P < 0.01. (C-E) U87 and LN229
cle distribution (C) and apoptosis (E) were detected. Cell invasion was
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lenti-AS-566-infected cells (Figure 2C). We also found a
significant decrease in cell invasion (Figure 2D) compared
to lenti-NC-treated cells. Apoptosis and cell cycle analysis
based on flow cytometry were performed with infected gli-
oma cells (U87 and LN229). A significant increase in the
number of apoptotic cells in lenti-AS-566-infected cells
(U87 and LN229) was also detected (Figure 2E). miR-566
inhibitor had no effect on the apoptosis of normal astro-
cytes (Additional file 1: Figure S1).
Having confirmed that a miR-566 inhibitor could deacti-
vate the EGFR pathway and inhibit the proliferative and in-
vasive behavior of glioma cells, we then demonstrated
whether the functions of miR-566 were mainly through the
EGFR pathway. U87 glioma cells were first infected withFigure 3 VHL is a direct functional target of miR-566. (A) A 3’ UTR frag
fused downstream of the firefly luciferase gene. (B) Western blot analysis o
or lenti-AS-566. (C) U87 and LN229 glioma cells were co-transfected with a
or lenti-AS-566 as indicated. After 48 h, firefly luciferase activity was measur
protein 48 h after transfection of the VHL expression plasmid or control pla
glioma cell proliferation (E), cell cycle distribution (F), invasion (G) and apolenti-AS-566 and then EGF was introduced to activate
EGFR signaling. Results showed that EGF partially reversed
the effects of lenti-AS-566 (Additional file 1: Figure S2).
VHL is a direct target of miR-566
We have clarified that a miR-566 inhibitor blocks prolifer-
ation and invasion and accelerates apoptosis in glioma
cells partially through the EGFR pathway. We then further
confirmed the target of miR-566. VHL was shown to be
involved in the tumorigenesis of glioma [9,21], and we
found that the 3’ UTR of VHL contained 2 potential
complimentary binding sites for miR-566. To validate this,
we performed luciferase reporter assays using 3’ UTR se-
quence fragments of the VHL transcript containing the
two predicted binding sites for miR-566 (Figure 3A).ment containing the predicted miR-566 targeting sites of VHL were
f VHL protein expression in U87 and LN229 cells treated with lenti-NC
human VHL 3’ UTR firefly luciferase reporter plasmid and lenti-NC
ed. (D) Western blot was used to detect the expression of the VHL
smid. (E-H) Overexpression of VHL rescued the effect of miR-566 on
ptosis (H). *P < 0.05.
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pression was significantly increased in lenti-AS-566-in-
fected glioma cells (Figure 3B). Transient cotransfection of
human U87 and LN229 cells with lenti-AS-566 and a wild-
type VHL 3’ UTR plasmid led to a significant increase in
luciferase reporter activity compared to infection with lenti-
NC (Figure 3C). ‘Rescue’-experiments were performed by
introducing a VHL expression plasmid lacking the miR-566
3’ UTR region into U87 and LN229 glioma cells to confirm
that the growth and invasion inhibition, cell cycle arrest
and apoptosis promotion by lenti-AS-566 was mediated, at
least in part, through the induction of VHL expression. The
successful transfection of the VHL plasmid was monitored
at the VHL protein level (Figure 3D). We then performed
colony formation assays, invasion assays and flow cytome-
try in VHL plasmid-transfected glioma cells. As shown in
Figure 3E and G, cell proliferation and invasion activity
were significantly inhibited in VHL-transfected glioma cells
(48 h after transfection). As shown in Figure 3 F and H, G1
cell cycle arrest was induced and apoptosis was increased
in VHL-transfected glioma cells.
miR-566 regulates the EGFR pathway through the
VHL/β-catenin and VHL/HIF-1α axis
TOP/FOP FLASH reporter and luciferase constructs
were introduced to detect the activity of canonical Wnt
signaling. TOPFLASH activity was measured in U87 and
LN229 cells infected with lenti-AS-566 or transfected
with VHL plasmid in the presence of LiCl or not. Our
Results showed that miR-566 inhibition or VHL overex-
pression could reduce the activity of the β-catenin/TCF4
pathway (Figure 4A). Western blot was used to examine
the expression of β-catenin both in the cytoplasm and
nucleus. We found that lenti-AS-566 or VHL plasmid
decreased the expression of β-catenin, especially in the
nucleus (Figure 4B). Confocal images showed the same
results (Figure 4C). Together, these findings suggested
that miR-566 regulated the activity of β-catenin/TCF sig-
naling through targeting VHL. The same results were
found in the HIF-1α pathway (Figure 4D and E). All to-
gether, we demonstrated that miR-566 could regulate
both β-catenin and HIF-1α signaling by targeting VHL.
miR-566 regulates the formation of the β-catenin/HIF-1α
complex and sensitizes glioma cells to nimotuzumab
therapy
VHL is responsible for the degradation of β-catenin and
HIF-1α [22], transcription factors that regulate the
expression of EGFR [23,24]. Therefore, we examined
whether HIF-1α forms a complex with β-catenin in gli-
oma cells by performing co-IP experiments. The results
showed that HIF-1α forms a complex with β-catenin
(Figure 5A). Furthermore, lenti-AS-566 partially inhib-
ited the formation of this complex. Western blot analysiswas used to determine the endogenous expression levels
of HIF-1α or β-catenin in the glioma cell lysates used in
these experiments (Figure 5A). These results suggested
that HIF-1α and β-catenin form a complex and coopera-
tively promote EGFR synthesis (Figure 5B).
Synergistic activity of miR-566 inhibition and nimotuzumab
in glioma cells and xenograft model
We have shown that miR-566 is an important oncomiR
in EGFR pathway regulation. We then determined if
miR-566 inhibition has synergistic effects with nimotu-
zumab administration. U87 and LN229 cells were treated
with nimotuzumab (100 μg/ml), and after 24 h, infected
with lenti-AS-566 or mock control. Cell proliferation
(Figure 5C), cell cycle distribution (Figure 5D), in vitro
invasion (Figure 5E) and apoptosis (Figure 5 F) were eval-
uated four days after-lentiviral infection. Lenti-AS-566 en-
hanced the effects of nimotuzumab with suppression of
cellular proliferation and invasion (Figure 5C and E). Flow
cytometric analysis revealed that more cells were arrested
in the G1 phase in the combination group (Figure 5D). In
addition, more apoptotic cells were detected after treat-
ment with nimotuzumab combined with lenti-AS-566
(Figure 5 F). To evaluate the effects of the combined ther-
apy of nimotuzumab and miR-566 inhibition on tumor
growth in vivo, we established tumors as intracranial xe-
nografts in nude mice. U87 cells were pretreated with
lentivirus containing a luciferase reporter. Compared with
nimotuzumab alone, the combination of nimotuzumab
with lenti-AS-566 significantly decreased the tumor bur-
den (Figure 6A and B). To analyze the survival times of
the treatment groups, we generated Kaplan-Meier survival
curves (Figure 6C), which demonstrated that combined
therapy significantly prolonged survival.
Discussion
To our knowledge, there are no reports on the function
of miR-566 in human cancers including glioma. In the
present study, we confirmed that miR-566 was upregu-
lated in human glioma cells, and repressing miR-566
could inactivate the EGFR pathway largely by targeting
VHL. Further studies demonstrated that miR-566 regu-
lated the VHL/β-catenin and VHL/HIF-1α axis in the
transcription of EGFR. In addition, miR-566 is respon-
sible for the formation of a β-catenin/HIF-1α complex.
Finally, we confirmed that miR-566 inhibition could be
synergistic with nimotuzumab therapy.
The EGFR pathway is activated in glioma and other
human cancers, including lung, breast and colorectal
[25-28]. The FDA has approved two types of anti-EGFR
agents: low molecular weight tyrosine kinase inhibitors
(TKIs) and mAbs that inhibit the EGFR extracellular do-
main. Clinically used anti-EGFR drugs include gefitinib,
erlotinib, lapatinib, cetuximab and panitumumab [29,30].
Figure 4 miR-566 regulated the β-catenin and HIF-1α pathway through VHL. (A) U87 and LN229 cells were treated with lenti-AS-566 or VHL
plasmid, and TOPFLASH activity was measured. The data are shown as the mean ± SD of 3 independent experiments. *, P < 0.05, compared with vector
control. (B, D) Cytoplasmic and nuclear proteins were prepared from lenti-AS-566 or VHL plasmid treated U87 and LN229 cells with or without the
addition of CoCl2. Cytoplasmic and nuclear β-catenin and HIF-1α expression levels were detected. β-actin and Histone H2A.X were used as loading
controls for cytoplasmic and nuclear proteins, respectively. (C, E) U87 cells were infected with lenti-AS-566 or VHL plasmid in the presence of LiCl,
CoCl2 or vehicle for 24 h. Confocal images show the translocation of β-catenin and HIF-1α in U87 cells. DAPI was used to stain the nuclei. Bar, 10 μm.
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lung cancer [31,32]. However, TKIs such as gefitinib and
erlotinib have had limited clinical success in treating
glioblastoma [33]. Moreover, all patients treated with
cetuximab or panitumumab for colorectal cancer suf-
fered from acute and subacute cutaneous side effects
[34]. Nimotuzumab is an anti-EGFR mAb developed at
the Center of Molecular Immunology in Havana, Cuba.
The clinical trials of nimotuzumab demonstrated that
severe cutaneous adverse events were extremely rare.
Furthermore, grade 3 and 4 acneiform eruptions com-
monly associated with other anti-EGFR mAbs were ab-
sent [35]. Glioblastoma patients could benefit from
nimotuzumab therapy, but the molecular expressionprofiles of GBM patients differ from one another. Person-
alized and combination therapy are needed.
MiRNAs are small, non-coding RNAs that can func-
tion as oncogenes or tumor suppressors by inhibiting
the expression of numerous target genes. EGFR signal-
ing can also be regulated by numerous miRNAs. For
example, miR-7 is down-regulated in human glioblast-
oma and directly inhibits EGFR expression by targeting
its 3’ UTR. In addition, miR-7 suppresses Akt pathway
activation independent of its EGFR inhibition [36]. We
previously demonstrated that miR-21 is upregulated in
glioma cells and that blocking its expression inactivates
EGFR/Akt signaling in a PTEN-independent manner
[8]. In the present study, for the first time, we
Figure 6 Lenti-AS-566 sensitized glioma cells to the effects of nimotuzumab in a mice xenograft model. (A) Bioluminescence images
from nimotuzumab and/or lenti-AS-566-treated animals at 3, 11 and 21 d after tumor implantation. (B) Tumor growth curves were evaluated. The
data are shown as the mean ± SD. **, P < 0.01. (C) Improved survival was observed in mice that were treated with the combined therapy.
Figures 5 miR-566 regulated the formation of the β-catenin/HIF-1α complex and sensitized glioma cells to nimotuzumab therapy.
(A) Freshly isolated cell lysates (U87 and LN229 either infected with lenti-AS-566 or left untreated) were used to immunoprecipitate β-catenin or
HIF-1α with specific rabbit antibodies. Rabbit whole immunoglobulin (IgG) was used as a control antibody for immunoprecipitation assays. The
immunoprecipitated complexes were subjected to Western blot analysis with specific antibodies against β-catenin and HIF-1α as indicated. (B) A
schematic diagram showed the miR-566 modulated EGFR pathway through VHL/β-catenin/HIF-1α. (C-F) U87 and LN229 cells were treated with
nimotuzumab (100 μg/ml) as indicated, and after 24 h, cells were infected with lenti-AS-566 or were untreated. Cell proliferation (C), cell cycle
distribution (D), in vitro invasion (E) and apoptosis (F) were evaluated 4 d after lentiviral infection. The data in all panels represent the mean ± SD.
*, P < 0.05.
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glioma cells. In vitro and in vivo studies demonstrated
that miR-566 inhibition deactivated EGFR/Akt signal-
ing and slowed the proliferation of glioma cells.
Studies have demonstrated that miRNAs influence the
response to chemotherapies for ovarian cancer, pancre-
atic cancer, bladder cancer and glioblastoma [37-40]. In
a study conducted by Liana Adam, miR-200 expression
regulated the epithelial-to-mesenchymal transition in
bladder cancer cells and reversed EGFR therapy resist-
ance [41]. In a study by Masahiro Seike, miR-21 was up-
regulated in the lung adenocarcinoma cell line H3255,
which contains an EGFR mutation and is hypersensitive
to EGFR TKI AG1478. The inhibition of miR-21 en-
hanced AG1478-induced apoptotic activity in these lung
cancer cells, which showed intermediate sensitivity to
AG1478. Another study demonstrated that epidermal
growth factor (EGF) and MET receptors modulated the
expression of miR-30b, miR-30c, miR-221 and miR-222.
These microRNAs are also responsible for gefitinib-
induced apoptosis and the epithelial-mesenchymal tran-
sition of NSCLC cells in vitro and in vivo by inhibiting the
expression of the genes encoding BCL2-like 11 (BIM),
apoptotic peptidase activating factor 1 (APAF-1), protein
kinase C ε (PKC-ε) and sarcoma viral oncogene homolog
(SRC) [42]. Our previous data demonstrated that miR-21
is involved in the regulation of anti-EGFR therapy [43].
Because miR-566 can regulate EGFR signaling, we
wondered whether it could sensitize glioma to the effects
of nimotuzumab in vitro and in vivo and its underlying
mechanism. We identified VHL as a potential functional
target of miR-566. A 3’ UTR luciferase assay was per-
formed to determine whether miR-566 binds to the 3’
UTR of the VHL gene. The relative luciferase level for
the VHL gene was significantly higher in lenti-AS-566-
infected glioma cells than in lenti-NC-infected controls,
and Western blot analysis confirmed these findings. The
results demonstrated that the expression of the VHL
protein is significantly upregulated in lenti-AS-566 in-
fected cells. These results suggest that VHL is a direct tar-
get of miR-566. Furthermore, we confirmed that miR-566
regulated the formation of a β-catenin/HIF-1α complex.
Both β-catenin and HIF-1α are important transcription
factors for EGFR. Finally, studies demonstrated that the
proliferation and invasion of glioma cells are attenuated
when co-treated with lenti-AS-566 and nimotuzumab.
The same results were confirmed in nude mice treated
with lenti-AS-566 and nimotuzumab.
Conclusions
In conclusion, this is the first report to demonstrate that
miR-566 expression is significantly increased in glioma
cells. miR-566 modulated the EGFR pathway through
direct targeting of VHL. We have identified the survival-related miRNA miR-566 as a regulator that influences
the response to anti-EGFR therapy. Our study could
have important implications for glioblastoma patients in
the development of novel therapeutics.
Materials and methods
Cell culture and chemical reagents
The human glioma cell lines U87, LN229, SNB19, LN308
and U251 were obtained from the American Type Culture
Collection (ATCC, Manassas, VA, USA). Human astro-
cytes (Invitrogen, Carlsbad, CA) were derived from human
brain tissues. The human glioma cell lines were cultured in
Dulbecco’s modified Eagle medium (DMEM) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS,
Hyclone, Waltham, MA). Astrocytes were cultured in
GIBCO Astrocyte Medium supplemented with N-2, FBS
and EGF. Cells were cultured in a humidified 10% CO2
atmosphere at 37˚C. LiCl (Acros Organics, New Jersey,
USA) and CoCl2 (Sinopharm Chemical, Shanghai, China)
were diluted in phosphate-buffered saline (PBS).
Lentiviral infection, gene transfection and qRT-PCR
Lentiviruses containing a miR-566 inhibitor segment
(lenti-AS-566) or negative control (lenti-NC) segment
were obtained from Genepharma (Shanghai, China). The
human glioma cell lines U87 and LN229 were infected
with the viral suspension. pcDNA3 and pcDNA3-VHL
plasmids were transfected using Lipofectamine 2000
(Invitrogen, Carlsbad, CA) following the manufacturer’s
instructions. Cells were harvested 48 h after infection or
transfection, and RNA and protein extractions were
performed. TRIzol (Invitrogen, Carlsbad, California) was
used to isolate total RNA. To detect miR-566, stem-loop
reverse transcription-polymerase chain reaction (RT-PCR)
was performed with a one-step RNA PCR kit (Takara,
Otsu, Shiga, Japan) according to the manufacturer’s in-
structions. Real-time PCR was performed by SYBR green
detection with a forward primer for the mature miRNA
sequence and a universal adaptor reverse primer. For the
analysis of EGFR, AKT1, AKT2 and AKT3 messenger
RNA (mRNA) expression, complementary DNA (cDNA)
synthesis was performed using random primers under
standard conditions. mRNA expression was quantified
using the ΔΔCt method. GAPDH served as the internal
control. All miRNA expression data were normalized to a
U6 small nuclear RNA from the same sample. All reac-
tions were performed in triplicate.
Plasmid construction and 3’ UTR analysis
The VHL expression plasmid pcDNA3-VHL was kindly
provided by Professor Jinquan Cheng (H. Lee Moffitt
Cancer Center and Research Institute, Florida). Glioma
cells were transfected with 100 ng TOP-FLASH or FOP-
FLASH plasmid (Millipore, Billerica, Massachusetts).
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plasmid with or without LiCl. At 24 h after transfection,
cell lysates were prepared with Dual Luciferase Lysis
Buffer (Promega, Agora, Fitchburg Center, Fitchburg,
Wisconsin), and luciferase activity was measured with a
microplate reader (Mithras LB940; Berthold Technologies
GmbH, Bad Wildbad, Germany). The transfection effi-
ciency was normalized using Renilla luciferase activity. Ex-
periments were performed at least 3 times; representative
data from a single experiment are shown.
The putative miR-566 binding site of the VHL 3’ UTR
was inserted into the pGL3-control vector (Promega,
Agora, Fitchburg Center, Fitchburg, Wisconsin) at the
Xba I site. For the VHL mutant reporter, the seed region
of the VHL 3’ UTR was deleted to remove all nucleo-
tides with complementarity to miR-566. For 3’ UTR
luciferase assays, glioma cells were co-treated with lenti-
NC or lenti-AS-566. Luciferase assays were performed
using the Dual-Luciferase Reporter Assay System (Promega,
Agora, Fitchburg Center, Fitchburg, Wisconsin) 48 h after
transfection.
Protein extraction, immunoblotting and
immunoprecipitation
Glioma cells were washed in PBS and lysed with ice-
cold RIPA buffer (Pierce, Brebieres, France) containing
the protease inhibitor PMSF (Sigma, St. Louis, MO).
Protein quantification was performed with a NanoDrop
ND-1000 Spectrophotometer (NanoDrop Technologies,
Wilmington, USA). A DUALXtract Cytoplasmic and
Nuclear Protein Extraction Kit (Dualsystems Biotech,
Schlieren, Switzerland) was used to isolate cytoplasmic
and nuclear proteins from cultured glioma cells.
The protein lysates were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred to a polyvinylidene difluoride membrane
(Roche, Basel, Switzerland). Membranes were immuno-
stained with specific antibodies according to standard pro-
tocols. Antibody-labeled protein bands on the membranes
were detected with a G:BOX F3 (Syngene, Cambridge, UK).
For immunoprecipitation, cells were lysed with IP lysis
buffer (Pierce, Rockford, USA). The cell lysates were then
subjected to immunoprecipitation with 1–5 mg of anti-
bodies and Protein A/G agarose beads (Pierce, Rockford,
USA) overnight at 4°C with constant agitation. Control
samples were incubated with agarose beads after immuno-
precipitation with a control immunoglobulin. The immu-
noprecipitated complexes were then washed with wash
buffer. The proteins were eluted, boiled and subjected to
SDS-PAGE analysis.
Immunofluorescence analysis
For immunofluorescence analysis, glioma cells were
seeded on poly-L-Lysine treated coverslips (BD, USA).The cells were then infected with lenti-566 or lenti-NC
with or without LiCl or CoCl2. After 48 h, the cells were
fixed in cold methanol for 2 min. The cells were then
washed 3 times in PBS and incubated in blocking buffer
for 30 min at room temperature. Next, the cells were
washed in PBS and incubated overnight at 4°C with β-
catenin and HIF-1α primary antibodies (Cell Signaling
Technology). The cells were again washed in PBS, followed
by incubation with a fluorescent secondary antibody for
1 h at room temperature. Nuclei were stained with DAPI
solution for 5 min. Confocal images of the cells were ac-
quired on a confocal microscope (FV500) with a 40 ×
water immersion lens and a 1.20 numerical aperture using
FluoView software (Olympus, Japan).
Colony formation, invasion, cell cycle distribution and
apoptosis analysis
For the colony formation assay, 2,000 glioma cells treated
with lenti-AS-566, lenti-NC, VHL plasmid or nimotuzu-
mab were plated in complete growth media in a fresh 6-
well plate and allowed to grow until visible colonies
formed. Cold methanol was used to fix the cell colonies,
and colonies were stained with 0.1% crystal violet for
15 min, washed, air dried, photographed and counted.
Corning transwell insert chambers (Corning, New York)
and BD Matrigel Invasion Chambers (BD Biosciences,
Bedford, MA) were used for the cell invasion experiment.
The prepared cells were added to the chamber and incu-
bated for 24 h at 37˚C. Cells that invaded the lower cham-
ber through the membrane were fixed with 20% methanol
and stained with 0.1% crystal violet, imaged and counted.
The cell cycle was analyzed by flow cytometry. Pre-
treated U87 and LN229 cells were washed with PBS,
trypsinized, fixed in 70% ethanol, washed and incubated
in phosphate-buffered saline containing propidium iod-
ide and RNase A (Sigma, St. Louis, MO) for 30 min at
37˚C. The cell cycle distributions were determined using
a DNA stain (4’,6-diamidino-2-phenylindole). The data
are the mean ± SD of 3 independent experiments.
Forty-eight hours after transfection, cells were har-
vested, washed, resuspended in staining buffer and ex-
amined using an Annexin V FITC Apoptosis Detection
Kit (KeyGEN Biotech, Nanjing, China). The apoptotic
distribution of the cells in each sample was then deter-
mined using fluorescence-activated cell sorting. Annexin
V-positive cells were regarded as apoptotic cells.
Intracranial model
Athymic mice (4 weeks of age) were intracranially im-
planted with 5 × 105 U87 cells (pretreated with lentivirus
containing the miR-566 inhibitor segment or negative
control segment) under the direction of a stereotactic in-
strument. Four days after cell implantation, mice were
injected intraperitoneally with nimotuzumab or control
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to detect intracranial tumor growth. Mice were anesthe-
tized, injected with D-luciferin (Promega, Agora, Fitchburg
Center, Fitchburg, Wisconsin) at 50 mg/mL intraperitone-
ally and imaged with the IVIS Imaging System (Caliper Life
Sciences) for 10–120 s. To quantify bioluminescence,
identical circular regions of interest were drawn around
the entire head of each animal, and the integrated flux
of photons (photons per second) in each region of
interest was determined by using the Living Images
software package (Caliper Life Sciences). Data were nor-
malized to the bioluminescence at the initiation of treat-
ment for each animal. The error bars shown in the figures
indicate SDs. All protocols involving animals were per-
formed in accordance with an approved Institutional
Animal Care and Use Committee protocol.
Additional file
Additional file 1: Figure S1. miR-566 inhibitor had no effect on the
apoptosis of normal astrocytes. (A), Astrocytes were infected or not with
lenti-AS-566. After 48 h, apoptosis was detected. (B), Western blot was
used to examine the expression of Bcl-2 in astrocytes. Figure S2. EGF
reversed the effects of miR-566 inhibition. (A) U87 cells were infected or
not with lenti-AS-566, 24 h later, EGF (10 ng/ml) was added into the
medium. Proliferation (A), cell cycle distribution (B), in vitro invasion (C),
and caspase3/7 activity (D) were evaluated 10 h after EGF treatment. Data
in all panels represent the mean ± SD. *, P < 0.05; **, P < 0.01.
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